Drug Trial News

RSS

Treating prenatal maternal infections could improve birth outcomes, study suggests

Clinical trials are underway to test an azithromycin-based combination treatment for pregnant women, "which could tackle some of the leading preventable causes of death for babies in sub-Saharan Africa," according to researchers from the London School of Hygiene & Tropical Medicine (LSHTM), who published a report on Wednesday in the Journal of the American Medical Association.

17 May 2012

Updated results from Amgen’s blinatumomab Phase 2 study on ALL

Amgen today announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study.

17 May 2012

Ibrutinib shows promise against CLL in the elderly

The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of elderly patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial.

17 May 2012

Data from Jennerex JX-594 clinical trials on cancer to be presented at ASCO annual meeting

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that data relating to the company's oncolytic virus therapy for cancer will be covered in three separate abstracts released today by the American Society of Clinical Oncology.

17 May 2012

Reformulated anti-HIV gel may be safe for use in both vagina, rectum

A change in the formulation of tenofovir gel, an anti-HIV gel developed for vaginal use, may make it safer to use in the rectum, suggests a study published online this week in the Journal of Antimicrobial Chemotherapy. In laboratory tests of rectal tissue, researchers from the Microbicide Trials Network (MTN) found that the reformulated gel was less harmful to the lining of the rectum than the original vaginal formulation, and just as effective in protecting cells against HIV.

17 May 2012

No significant differences in absorption between tablet and softgel capsule forms of folic acid

The bioavailability of folic acid does not significantly differ between delivery in standard tablet or softgel capsule forms, according to research published in this month's Journal of the Academy of Nutrition and Dietetics. Folic Acid helps support a women's pregnancy and development of a healthy newborn.

17 May 2012

Combination of daclizumab and vaccine improves survival of breast cancer patients

A team from the Perelman School of Medicine and the Abramson Family Cancer Research Institute at the University of Pennsylvania found that the FDA-approved drug daclizumab improved the survival of breast cancer patients taking a cancer vaccine by 30 percent, compared to those patients not taking daclizumab.

17 May 2012

May issue of NeuroPerspective assesses field of stroke therapeutics

NeuroPerspective, the independent, monthly review of the neurotherapeutics area, has released its May issue, which assesses the field of therapeutics for stroke.

17 May 2012

Results from Boehringer Ingelheim’s LUX-Lung 3 Phase III trial on stage IIIB or IV NSCLC

Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.

17 May 2012

Most depressed patients must make multiple attempts before finding an effective antidepressant

UT Southwestern Medical Center psychiatrists are leading a national clinical trial to find biomarkers that can better predict how people suffering from depression will respond to medications so physicians eventually can personalize treatments.

16 May 2012

First patient included in the phase II study of Amphinex® in head and neck cancer patients

PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been included in the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients, called the ENHANCE study. The first patient was included at the National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Thoraxklinik Heidelberg and Deutsche Krebshilfe (German Cancer Aid).

16 May 2012

Achaogen’s plazomicin and levofloxacin safe and effective in treating cUTI, acute pyelonephritis

Achaogen, Inc. announced today that all objectives were met in the company's multi-national Phase 2 study of plazomicin compared to levofloxacin for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis in adults.

16 May 2012

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.

16 May 2012

Galectin Therapeutics commences Phase 1/2 trial of new treatment combination for advanced MM

Galectin Therapeutics, the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer, today announced that the first patient has been dosed in a Phase 1/2 trial evaluating the safety and efficacy of a novel treatment combination for the treatment of advanced metastatic melanoma.

16 May 2012

Positive data from Theraclone Sciences’ TCN-032 Phase 1 trial on influenza A infection

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced positive top-line data from its Phase 1 trial of TCN-032, a broadly protective, fully human monoclonal antibody, being developed for the treatment of influenza A infections.

16 May 2012

Juventas begins enrollment in JVS-100 Phase IIa study for Rutherford Class 4 or 5 CLI

Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, is pleased to report that it is actively enrolling patients in a placebo-controlled, randomized double-blinded Phase IIa study evaluating the safety and efficacy for JVS-100 in patients with Rutherford Class 4 or 5 critical limb ischemia.

16 May 2012

Novelos completes I-131-CLR1404 Phase 1b trial on advanced solid tumors

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it has successfully completed the first cohort in a U.S. multi-center Phase 1b dose-escalation trial of its cancer-targeted molecular radiotherapeutic compound I-131-CLR1404 (HOT) in cancer patients with advanced solid tumors.

16 May 2012

Svelte completes enrollment in DIRECT drug-eluting stent study

Svelte Medical Systems today announced completion of enrollment in the DIRECT (Direct Implantation of Rapamycin-eluting stent with bio-Eroding Carrier Technology) study conducted at four investigational sites in New Zealand.

15 May 2012

Cubist announces results from CB-5945 Phase 2 studies on chronic non-cancer pain, OIC

Cubist Pharmaceuticals, Inc. today announced that the results from the Phase 2 studies of CB-5945 (formerly ADL5945) in patients with chronic non-cancer pain and opioid-induced constipation (OIC) will be presented at the 31st Annual Scientific Meeting of the American Pain Society taking place May 16 to 19, 2012, in Honolulu and during Digestive Disease Week 2012 taking place May 19 to 22, 2012, in San Diego.

15 May 2012

Pearl Therapeutics to present PT003 Phase 2b study on COPD at ATS meeting

Pearl Therapeutics Inc. announced plans to make 11 presentations at upcoming medical meetings to report clinical and product development information pertaining to PT003 (GFF MDI), a proprietary, fixed-dose combination of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist.

15 May 2012

Drug Trial News

Treating prenatal maternal infections could improve birth outcomes, study suggests

Updated results from Amgen’s blinatumomab Phase 2 study on ALL

Ibrutinib shows promise against CLL in the elderly

Data from Jennerex JX-594 clinical trials on cancer to be presented at ASCO annual meeting

Reformulated anti-HIV gel may be safe for use in both vagina, rectum

No significant differences in absorption between tablet and softgel capsule forms of folic acid

Combination of daclizumab and vaccine improves survival of breast cancer patients

May issue of NeuroPerspective assesses field of stroke therapeutics

Results from Boehringer Ingelheim’s LUX-Lung 3 Phase III trial on stage IIIB or IV NSCLC

Most depressed patients must make multiple attempts before finding an effective antidepressant

First patient included in the phase II study of Amphinex® in head and neck cancer patients

Achaogen’s plazomicin and levofloxacin safe and effective in treating cUTI, acute pyelonephritis

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Galectin Therapeutics commences Phase 1/2 trial of new treatment combination for advanced MM

Positive data from Theraclone Sciences’ TCN-032 Phase 1 trial on influenza A infection

Juventas begins enrollment in JVS-100 Phase IIa study for Rutherford Class 4 or 5 CLI

Novelos completes I-131-CLR1404 Phase 1b trial on advanced solid tumors

Svelte completes enrollment in DIRECT drug-eluting stent study

Cubist announces results from CB-5945 Phase 2 studies on chronic non-cancer pain, OIC

Pearl Therapeutics to present PT003 Phase 2b study on COPD at ATS meeting

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News